Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B202105176L | Other Identifier | Tri-Service General Hospital, National Defense Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the efficacy of the Fespixon cream for prevention and/or appearance reduction of different types of linear scars during the 12-week treatment phase, which is assessed by the blinded independent evaluator.
Methods: This study was designed as a prospective, double-blind, placebo-controlled trial involving 50 patients with linear scars. Bounded by the midpoint of the scar, each patient received a topical scar formulation consisting of fespixon cream on one side of scar, and placebo cream on the other side of scar. Treatment was given twice a day for 84 days. Assessments of the scars were performed at visit 1, 2, 3 following the onset of topical application using three methods: a clinical assessment using the Vancouver Scar Scale/ modified Vancouver Scar Scale, a photographic assessment to establish before and after treatment improvements, and at the end of the study period, patients completed a final satisfaction questionnaire.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fespixon cream | Experimental | Fespixon cream contains 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%) with appearance in yellow-green to light green color. Fespixon cream will be applied twice daily for up to 12 weeks to the linear wound. |
|
| Placebo Cream | Placebo Comparator | Placebo cream with appearance in yellow-green to light green color, same appearance as Fespixon cream, will be applied twice daily for up to 12 weeks to the linear wound. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fespixon cream | Drug | Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days. |
| Measure | Description | Time Frame |
|---|---|---|
| VSS total scores at Day 1 and Week 12 assessed by 3 blind evaluators | The VSS scores, assessed by 3 blind evaluators, changed from Day 1 to Week 12 will be used as an objective evidence. | 12-week |
| Measure | Description | Time Frame |
|---|---|---|
| mVSS individual scores at Day 1 and Week 12 assessed by a Principal Investigator | The mVSS scores, assessed by a Principal Investigator, changed from Day 1 to Week 12 will be used as an auxiliary evidence. | 12-week |
| Hue feature-Red values via digital analysis at Day 1 and Week 12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subjects who have previous neck or abdominal trauma that will affect the surgical incision site.
After radiation therapy for cervical/abdominal cancer, or previous medical history with chemo-therapy or targeted therapy for any reason.
Laboratory values at Screening of:
Note: The investigator will decide which of the following laboratory tests should be performed considering the condition of the subject.
Subject is currently receiving immunosuppressant or systemic corticosteroids.
Has any other factor which may, in the opinion of the investigator, compromise participation in the study.(Including subjects with medical history of keloid or hypertrophic scar).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shao-Cheng Liu, PhD | Tri-Service General Hospital, National Defense Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tri-Service General Hospital, National Defense Medical Center | Taipei | 114 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002921 | Cicatrix |
| ID | Term |
|---|---|
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
The patient's wound was treated with a placebo or therapeutic ointment on the right side and a placebo or therapeutic ointmenton the left side.
Not provided
Not provided
Participants and outcomes (VSS score) assessors do not know which side is applied with the therapeutic ointment.
|
| Placebo Cream | Drug | Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days. |
|
1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin |
| 12-week |
| Hue feature-Green values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| Hue feature-Blue values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| CIELab-lightness values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| CIELab-a values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| CIELab-b values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| Textual features-Contrast (Con) values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| Textual features-Homogeneity (Hom) values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| Textual features-Correlation (Cor) values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| Textual features-Entropy (ENT) values via digital analysis at Day 1 and Week 12 | 1. Using the data of Day1 as baseline, relative Δ ratio represents the difference of Δ ratio between Week 12 and Day1 out of baseline. NOTE1: Relative Δ ratio = (Week 12 Δ ratio - Day1 Δ ratio)/ Day1 Δ ratio NOTE2: Difference ratio= Δ ratio = Δ(scar-skin)/skin | 12-week |
| VAS (Visual Analogue Scale) score at Week 12 | VAS score (on a scale from 0 to 10) at Week 12 are used to present the satisfaction of participants. Zero means participants feel "not at all satisfied" and 10 means participants feel "completely satisfied". | 12-week |